NCT04860700View on ClinicalTrials.gov

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 17, 2023

Study Completion Date

October 17, 2023

Conditions
Malignant Adrenal Gland PheochromocytomaMalignant ParagangliomaPheochromocytoma, MetastaticParaganglioma, MalignantParaganglioma, Extra-Adrenal
Interventions
DRUG

anlotinib hydrochloride

Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER